Darifenacin treatment for overactive bladder in patients who expressed dissatisfaction with prior extended-release antimuscarinic therapy

International Journal of Clinical Practice

Volumn 62, Issue 11, 2008, Pages 1664-1674

  Zinner, N ^a   Kobashi, K C ^b   Ebinger, U ^c   Viegas, A ^c   Egermark, M ^c   Quebe Fehling, E ^c   Koochaki, P ^d  

^a Western Clinical Research   (United States)

^b VIRGINIA MASON MEDICAL CENTER   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

^d PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DARIFENACIN; MUSCARINIC RECEPTOR BLOCKING AGENT; OXYBUTYNIN; TOLTERODINE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONSTIPATION; DRUG DOSE TITRATION; DRUG WITHDRAWAL; DRY EYE; DYSPEPSIA; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OPEN STUDY; OUTCOME ASSESSMENT; OVERACTIVE BLADDER; PARAMETER; PATIENT SATISFACTION; PERCEPTION; PRIORITY JOURNAL; SCORING SYSTEM; SYMPTOM; UPPER RESPIRATORY TRACT INFECTION; URGE INCONTINENCE; URINARY FREQUENCY; URINARY TRACT INFECTION; URINARY URGENCY; XEROSTOMIA;

ADOLESCENT; ADULT; AGED; BENZOFURANS; FEMALE; HUMANS; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PATIENT SATISFACTION; PYRROLIDINES; TREATMENT OUTCOME; URINARY BLADDER, OVERACTIVE; URINATION; YOUNG ADULT;

EID: 54049108876     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2008.01893.x     Document Type: Article

References (14)

1. D'Souza A, Smith MJ, Miller L-A, Doyle J, Ariely R. Persistence, adherence, and switch rates among extended-release and immediate-release over-active bladder (OAB) medications in a regional managed care plan. J Manag Care Pharm 2008 14 : 291 301.
2. 3 receptor subtype (abstract). http://www.icsoffice.org/ publications/2002/pdf/445.pdf (accessed 27 August 2008).
3. 3-mediated phosphoinositide responses in guinea pig urinary bladder and submandibular salivary gland. J Pharmacol Exp Ther 2004 310 : 1255 65.
4. Coyne KS, Matza LS, Kopp Z, Abrams P. The validation of the patient perception of bladder condition (PPBC): a single-item global measure for patients with overactive bladder. Eur Urol 2006 49 : 1079 86.
5. Garely AD, Kaufman JM, Sand PK, Smith N, Andoh M. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT). Clin Ther 2006 28 : 1935 46.
6. Chapple C, DuBeau C, Ebinger U, Rekeda L, Viegas A. Darifenacin treatment of patients ≥65 years with overactive bladder: results of a randomized, controlled, 12-week trial. Curr Med Res Opin 2007 23 : 2347 58.
7. Steers W, Corcos J, Foote J, Kralidis G. An investigation of dose titration with darifenacin, an M3-selective receptor antagonist. BJU Int 2005 95 : 580 6.
8. Karram M, Chancellor M, Andoh M. Solifenacin reduces overactive bladder symptoms and improves health-related quality of life in patients previously treated with tolterodine (abstract). http://www.icsoffice.org/publications/2006/ pdf/0332.pdf (accessed 12 January 2007).
9. van Kerrebroeck P, Haab F, Millard R. Antimuscarinic therapy for overactive bladder syndrome: possible benefits of switching to solifenacin (abstract). http://www.icsoffice.org/publications/2005/pdf/0571.pdf (accessed 21 May 2008).
10. Haab F, Corcos J, Siami P et al. Long-term treatment with darifenacin for overactive bladder: results of a 2-year, open-label extension study. BJU Int 2006 98 : 1025 32.
11. Hill S, Elhilali M, Millard R, Lheritier K, Kawakami F, Steel M. Long-term darifenacin treatment for overactive bladder in patients aged 65 years and older: analysis of results from a 2-year, open-label extension study. Curr Med Res Opin 2007 23 : 2697 704.
12. FDA Report. Guidance for Industry. Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. http://www.fda.gov/ CDER/GUIDANCE/5460dft.pdf (accessed 27 August 2008).
13. Brubaker L, Chapple C, Coyne KS, Kopp Z. Patient-reported outcomes in overactive bladder: importance for determining clinical effectiveness of treatment. Urology 2006 68 : 3 8.
14. Marschall-Kehrel D, Roberts RG, Brubaker L. Patient-reported outcomes in overactive bladder: the influence of perception of condition and expectation for treatment benefit. Urology 2006 68 : 29 37.